Ashlyn Gates
Durham, NCNPI 1487277208
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 451 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,358 and has fallen 96.9% since, to $73 in 2025.
Across 451 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$827
- Sunovion Pharmaceuticals Inc.$771
- Otsuka America Pharmaceutical, Inc.$696
- Ironshore Pharmaceuticals Inc.$695
- Neurocrine Biosciences, Inc.$641
- plus $3K from 14 others
What the payments were for
- Food & beverage$7,834100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $1,210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $827 |
| Sunovion Pharmaceuticals Inc. | 41 | $771 |
| Otsuka America Pharmaceutical, Inc. | 38 | $696 |
| Ironshore Pharmaceuticals Inc. | 38 | $695 |
| Neurocrine Biosciences, Inc. | 41 | $641 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $628 |
| Alkermes, Inc. | 23 | $430 |
| Supernus Pharmaceuticals, Inc. | 16 | $403 |
| Johnson & Johnson | 17 | $369 |
| Idorsia Pharmaceuticals US Inc | 10 | $304 |
| Axsome Therapeutics, Inc. | 12 | $227 |
| Lundbeck LLC | 10 | $211 |
| Corium, LLC | 9 | $143 |
| Teva Pharmaceuticals USA, Inc. | 7 | $140 |
| Neos Therapeutics, LP | 3 | $53 |
| Almatica Pharma LLC | 2 | $44 |
| Noven Therapeutics, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 13 | $22,310 |
| Hydroxyzine Hcl | 13 | $184 |
| Lamotrigine | 18 | $111 |
| Trazodone Hcl | 14 | $99 |
| Fluoxetine Hcl | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,210 | $22,31013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.